TELA Bio, Inc. (TELA)Healthcare | Medical Devices | Malvern, United States | NasdaqGM
0.62 USD
-0.01
(-1.952%) ⇩
(April 21, 2026, 11:54 a.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:51 a.m. EDT
TELA Bio is in a severe value trap with deteriorating fundamentals confirmed by consecutive analyst downgrades and a lagging revenue quarter. The stock is trading at a 3 month high relative to its 200-day moving average but still 46% below it, heavily reliant on a 1-year recovery while long-term growth metrics are deteriorating. The lack of positive momentum in price action combined with the heavy downside protection in options signals that the market is pricing in further correction before any intervention. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.115657 |
| AutoTheta | 0.173152 |
| MSTL | 0.253914 |
| AutoETS | 0.255179 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 53% |
| H-stat | 3.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.285 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 913.258 |
| Revenue per Share | 1.71 |
| Market Cap | 27,676,394 |
| Forward P/E | -1.10 |
| Beta | 0.99 |
| Profit Margins | -48.37% |
| Website | https://www.telabio.com |
As of April 19, 2026, 12:51 a.m. EDT: Options sentiment is overwhelmingly bearish and asymmetric. Call activity is extremely muted, with almost no OTM positioning, while slightly ITM puts (strike 2.5) show significant Open Interest (50 contracts) and volume (20 contracts) for July expiration. This heavy put positioning acts as a defensive hedge against downside, capping returns if a short covering rally occurs but providing little incentive for bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.32872343 |
| Address1 | 1 Great Valley Parkway |
| Address2 | Suite 24 |
| All Time High | 23.545 |
| All Time Low | 0.501 |
| Ask | 0.771 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 134,940 |
| Average Daily Volume3 Month | 207,036 |
| Average Volume | 207,036 |
| Average Volume10Days | 134,940 |
| Beta | 0.993 |
| Bid | 0.434 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.142 |
| City | Malvern |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6186 |
| Current Ratio | 4.205 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.6436 |
| Day Low | 0.5876 |
| Debt To Equity | 913.258 |
| Display Name | TELA Bio |
| Earnings Call Timestamp End | 1,774,384,200 |
| Earnings Call Timestamp Start | 1,774,384,200 |
| Earnings Timestamp | 1,774,382,400 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -32,745,000 |
| Ebitda Margins | -0.40791 |
| Enterprise To Ebitda | -1.07 |
| Enterprise To Revenue | 0.437 |
| Enterprise Value | 35,040,176 |
| Eps Current Year | -0.674 |
| Eps Forward | -0.562 |
| Eps Trailing Twelve Months | -0.83 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7422 |
| Fifty Day Average Change | -0.123600006 |
| Fifty Day Average Change Percent | -0.16653194 |
| Fifty Two Week Change Percent | -32.872345 |
| Fifty Two Week High | 2.2 |
| Fifty Two Week High Change | -1.5814 |
| Fifty Two Week High Change Percent | -0.7188182 |
| Fifty Two Week Low | 0.501 |
| Fifty Two Week Low Change | 0.117600024 |
| Fifty Two Week Low Change Percent | 0.23473059 |
| Fifty Two Week Range | 0.501 - 2.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,573,223,400,000 |
| Float Shares | 19,466,535 |
| Forward Eps | -0.562 |
| Forward P E | -1.1007118 |
| Free Cashflow | -16,954,000 |
| Full Exchange Name | NasdaqGM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.68167 |
| Gross Profits | 54,721,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.084230006 |
| Held Percent Institutions | 0.70528 |
| Implied Shares Outstanding | 44,740,371 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. |
| Long Name | TELA Bio, Inc. |
| Market | us_market |
| Market Cap | 27,676,394 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_225019977 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -38,831,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 28,186,433 |
| Number Of Analyst Opinions | 5 |
| Open | 0.624 |
| Operating Cashflow | -28,219,000 |
| Operating Margins | -0.31856 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 484 320 2930 |
| Previous Close | 0.631 |
| Price Eps Current Year | -0.9178041 |
| Price Hint | 4 |
| Price To Book | 4.356338 |
| Price To Sales Trailing12 Months | 0.34476978 |
| Profit Margins | -0.48372 |
| Quick Ratio | 3.404 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0123999715 |
| Regular Market Change Percent | -1.9524441 |
| Regular Market Day High | 0.6436 |
| Regular Market Day Low | 0.5876 |
| Regular Market Day Range | 0.5876 - 0.6436 |
| Regular Market Open | 0.624 |
| Regular Market Previous Close | 0.631 |
| Regular Market Price | 0.6186 |
| Regular Market Time | 1,776,786,860 |
| Regular Market Volume | 31,986 |
| Return On Assets | -0.25117 |
| Return On Equity | -2.23353 |
| Revenue Growth | 0.182 |
| Revenue Per Share | 1.71 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 44,740,371 |
| Shares Percent Shares Out | 0.0154 |
| Shares Short | 690,940 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 629,667 |
| Short Name | TELA Bio, Inc. |
| Short Percent Of Float | 0.019 |
| Short Ratio | 4.46 |
| Source Interval | 15 |
| State | PA |
| Symbol | TELA |
| Target High Price | 3.25 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.25 |
| Target Median Price | 2.0 |
| Total Cash | 50,845,000 |
| Total Cash Per Share | 1.136 |
| Total Debt | 57,654,000 |
| Total Revenue | 80,275,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.25493 |
| Two Hundred Day Average Change | -0.63633 |
| Two Hundred Day Average Change Percent | -0.50706416 |
| Type Disp | Equity |
| Volume | 31,986 |
| Website | https://www.telabio.com |
| Zip | 19,355 |